Exagen [XGN] vs Fonar [FONR] Detailed Stock Comparison

Exagen Inc.

NASDAQ
Loading...

Fonar Corporation

NASDAQ
Loading...

TLDR: Quick Comparison Summary

Based on 20 vital metrics comparison: Exagen Inc. wins in 3 metrics, Fonar Corporation wins in 15 metrics, with 0 ties. Fonar Corporation appears stronger overall.

View Metrics Details

Vital Metrics Comparison

Metric Exagen Inc. Fonar Corporation Better
P/E Ratio (TTM) N/A 16.35 N/A
Price-to-Book Ratio 3.52 0.70 Fonar Corporation
Debt-to-Equity Ratio 158.55 24.44 Fonar Corporation
PEG Ratio -5.96 2.37 Fonar Corporation
EV/EBITDA -5.01 6.37 Fonar Corporation
Profit Margin (TTM) -29.97% 7.13% Fonar Corporation
Operating Margin (TTM) -29.91% 11.74% Fonar Corporation
EBITDA Margin (TTM) N/A 11.74% N/A
Return on Equity -147.85% 6.01% Fonar Corporation
Return on Assets (TTM) -17.12% 3.16% Fonar Corporation
Free Cash Flow (TTM) $-14.27M $7.45M Fonar Corporation
1-Year Return -28.35% 31.72% Fonar Corporation
Price-to-Sales Ratio (TTM) 0.97 1.12 Exagen Inc.
Enterprise Value $59.91M $95.88M Fonar Corporation
EV/Revenue Ratio 0.90 0.90 Exagen Inc.
Gross Profit Margin (TTM) 55.35% 37.95% Exagen Inc.
Revenue per Share (TTM) $3 $16 Fonar Corporation
Earnings per Share (Diluted) $-0.93 $1.15 Fonar Corporation
Beta (Stock Volatility) 1.94 0.99 Fonar Corporation
Short % of Float 7.67% 1.18% Fonar Corporation

Exagen Inc. vs Fonar Corporation Stock Performance Analysis

Loading Price Chart...

XGN
FONR

Performance Comparison

Short-term Returns

Stock1D1W1M3M6MYTD
Exagen Inc.-6.02%4.33%55.48%35.77%-32.11%-20.20%
Fonar Corporation-0.10%0.95%0.90%2.86%32.66%3.08%

Long-term Returns

Stock1Y3Y5Y10Y15Y20Y
Exagen Inc.-28.35%61.17%-62.64%-70.71%-70.71%-70.71%
Fonar Corporation31.72%13.49%5.18%16.25%827.18%55.92%

Performance & Financial Health Analysis: Exagen Inc. vs Fonar Corporation

MetricXGNFONR
Market Information
Market Cap i$64.46M$118.64M
Market Cap CategoryMicro capMicro cap
10 Day Avg. Volume i206,13851,896
90 Day Avg. Volume i219,92947,295
Last Close$4.53$19.09
52 Week Range$2.59 - $12.23$13.62 - $19.16
% from 52W High-62.96%-0.37%
All-Time High$29.86 (Dec 23, 2019)$310.00 (Dec 06, 1982)
% from All-Time High-84.83%-93.84%
Growth Metrics
Quarterly Revenue Growth0.22%0.02%
Quarterly Earnings Growth0.22%0.05%
Financial Health
Profit Margin (TTM) i-0.30%0.07%
Operating Margin (TTM) i-0.30%0.12%
Return on Equity (TTM) i-1.48%0.06%
Debt to Equity (MRQ) i158.5524.44
Cash & Liquidity
Book Value per Share (MRQ)$0.76$27.01
Cash per Share (MRQ)$1.34$8.10
Operating Cash Flow (TTM) i$-13,625,000$9.23M
Levered Free Cash Flow (TTM) i$-10,364,500$2.44M
Dividends
Last 12-Month Dividend Yield iN/AN/A
Last 12-Month Dividend iN/A$0.00

Valuation & Enterprise Metrics Analysis: Exagen Inc. vs Fonar Corporation

MetricXGN (Apr 24, 2026)FONR (Apr 24, 2026)
Price Ratios
P/E Ratio (TTM) iN/A16.35
Forward P/E i-5.96N/A
PEG Ratio i-5.962.37
Price to Sales (TTM) i0.971.12
Price to Book (MRQ) i3.520.70
Market Capitalization
Market Capitalization i$64.46M$118.64M
Enterprise Value i$59.91M$95.88M
Enterprise Value Metrics
Enterprise to Revenue i0.900.90
Enterprise to EBITDA i-5.016.37
Risk & Other Metrics
Beta i1.940.99
Book Value per Share (MRQ) i$0.76$27.01

Financial Statements Comparison: Exagen Inc. vs Fonar Corporation

Financial Metrics

Loading Financial Charts...

Revenue

Operating Margin

Profit Margin

Long Term Debt

Income Flow Analysis

Financial Statements Comparison

Income Statement

MetricXGN (2025)FONR (2025)
Revenue/Sales i66.58M104.35M
Cost of Goods Sold i27.78M61.44M
COGS % of Revenue i41.7%58.9%
Gross Profit i38.80M42.91M
Gross Margin i58.3%41.1%
Research & Development i6.25M1.58M
Operating Income (EBIT) i-14.07M11.60M
Operating Margin i-21.1%11.1%
EBITDA i-11.66M16.33M
EBITDA Margin i-17.5%15.7%
Pre-Tax Income i-19.90M13.78M
Pre-Tax Income % of Revenue i-29.9%13.2%
Income Tax i51,0003.11M
Income Tax % of Revenue i0.1%3.0%
Net Income (Profit) i-19.95M10.67M
Profit Margin i-30.0%10.2%

Balance Sheet & Liquidity Metrics

MetricXGN (2025)FONR (2025)
Cash & Equivalents i32.22M56.33M
Total Current Assets i48.89M144.67M
Total Current Assets % of Revenue i73.4%138.6%
Total Current Liabilities i14.16M17.12M
Total Current Liabilities % of Revenue i21.3%16.4%
Long-Term Debt i22.70M35.29M
Long-Term Debt % of Revenue i34.1%33.8%
Total Shareholders Equity i17.45M160.10M
Retained Earnings i-314.28M-5.29M
Retained Earnings % of Revenue i-472.1%-5.1%
Property, Plant & Equipment i9.67M77.28M

Cash Flow Statement Comparison

MetricXGN (2025)FONR (2025)
Operating Cash Flow i-16.79M9.20M
Operating Cash Flow % of Revenue i-25.2%8.8%
Capital Expenditures i-626,000-3.79M
Free Cash Flow i-14.27M7.45M
FCF Margin i-21.4%7.1%
Debt Repayment i-20.79M-113,940
Common Stock Repurchase iN/A-1.81M

Short Interest & Institutional Ownership Analysis

MetricXGNFONR
Shares Short i1.53M70,961
Short Ratio i4.901.33
Short % of Float i7.67%1.18%
Shares Outstanding i22.91M6.30M
Float Shares i16.17M5.13M
% Held by Insiders i18.09%12.28%
% Held by Institutions i59.71%45.39%
% Held by Public i22.20%42.33%

Dividend Analysis & Yield Comparison: Exagen Inc. vs Fonar Corporation

MetricXGNFONR
Last 12-Month Dividend iN/A$0.00
Last 12-Month Dividend Yield iN/AN/A
3-Year Avg Annual Dividend iN/A$0.00
3-Year Avg Dividend Yield iN/AN/A
3-Year Total Dividends iN/A$0.00
Ex-Dividend DateN/AN/A